-
Innovation Ranking
Innovation Ranking – Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery and development of new chemical entities (NCEs). It develops and markets branded and generic formulations. The company's formulations business encompasses therapeutic areas such as dermatology, respiratory, and oncology. It has also presence in other therapeutic areas such as diabetes, cardiovascular and oral contraceptives. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark has manufacturing facilities in India, Argentina, the US and Czech Republic. The company markets its products in North America,...
-
Product Insights
NewDry Powder Inhaler Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Dry powder inhaler devices deliver medication to the lungs in the form of a dry powder. GlobalData's Medical Devices sector report, “Dry Powder Inhaler Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" provides comprehensive information about the Dry Powder Inhaler Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Dry Powder Inhaler Devices report...
-
Company Insights
Innovation and Patenting activity of Glenmark Pharmaceuticals Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Glenmark Pharmaceuticals Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewSeasonal Allergic Rhinitis – Drugs In Development, 2024
Empower your strategies with our Seasonal Allergic Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions. Seasonal allergic rhinitis (SAR), commonly referred to as hay fever, is an inflammatory condition affecting the upper airways in response to exposure to airborne allergens, typically pollen from trees, grasses, and weeds, particularly prevalent in certain seasons. This condition manifests in sensitized individuals, giving rise to symptoms such as sneezing, nasal congestion, a runny nose, itchy or watery eyes, and fatigue....
-
Product Insights
NewAllergic Asthma – Drugs In Development, 2024
Empower your strategies with our Allergic Asthma – Drugs In Development, 2024 report and make more profitable business decisions. Allergic asthma is a type of asthma triggered by exposure to allergens, substances that induce an allergic reaction in susceptible individuals. When someone with allergic asthma encounters these triggers, their immune system responds by inflaming and constricting the airways, leading to symptoms of asthma. Common allergens that can trigger asthma include pollen, dust mites, pet dander, mold, cockroach droppings, and certain foods....
-
Product Insights
NewChronic Urticaria Or Hives – Drugs In Development, 2024
Empower your strategies with our Chronic Urticaria Or Hives – Drugs In Development, 2024 report and make more profitable business decisions. Chronic urticaria, also known as hives, are outbreaks of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors...
-
Product Insights
NewAllergic Rhinitis – Drugs In Development, 2024
Empower your strategies with our Allergic Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions. Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy or runny nose, sneezing, swollen...
-
Product Insights
NewHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite, and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infections with the...
-
Product Insights
Inhalers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Inhalers Pipeline Market Report Overview Inhalers deliver medication to the lungs. The inhalers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segment · Dry Powder Inhaler Devices Key Territories · The US · Europe · Australia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GRC-54276 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GRC-54276 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GRC-54276 in Breast Cancer Drug Details: GRC-54276 is under development for the...